The success of semaglutide and tirzepatide is evident in their 2024 sales volumes and revenues, creating a clearer picture of ...

I don’t feel like I’m dragging anymore.” So far, he has experienced no side effects and plans to continue microdosing as long ...

Lilly's Zepbound price cuts ranged from $50 to $100, depending on the dosage, for consumers who pay cash via the drugmaker's LillyDirect website.

Eli Lilly cuts cash prices for Zepbound weight-loss vials on LillyDirect, offering doses from $299 to $449 as demand for ...

While Ozempic has gained global popularity for treating type-2 diabetes and consequently triggering weight loss, many are now ...

India’s pharmaceutical giants are hoping to earn fat profits as their customers get thinner. With the patent for blockbuster diabetes and weight-loss drugs Ozempic and Wegovy set to expire in March, ...

Orforglipron is Lilly’s oral GLP-1 in phase 3 development as a treatment for diabetes and obesity. The FDA is expected to approve the drug in March 2026. Lilly’s November news release states that the ...

Eli Lilly has cut cash prices for its weight-loss drug Zepbound on LillyDirect, lowering monthly costs to $299–$449. The move ...

Pancreatitis, vision loss ... the risks of drugs such as Ozempic can sound scary. But what does the evidence show?

The next-generation “GLP-1 plus” drugs will be tailored to the health needs of individual patients.

Shaily Engineering Plastics Ltd and Gland Pharma Ltd, involved in the making and filling of injectable pens for semaglutide, ...